香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1776） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，廣發証券股份有限公司（「本公司」）在深圳 證券交易所網站( http://www.szse.cn )刊發的《廣發証券股份有限公司2024年面向 專業投資者公開發行短期公司債券（第六期）（品種二）2025年兌付兌息及摘牌公 告》。茲載列如下，僅供參閱。 GF SECURITIES CO., LTD. 廣發証券股份有限公司 承董事會命 廣發証券股份有限公司 林傳輝 董事長 中國，廣州 2025年6月12日 於本公告日期，本公司董事會成員包括執行董事林傳輝先生、秦力先生、孫曉燕 女士及肖雪生先生；非執行董事李秀林先生、尚書志先生及郭敬誼先生；獨立非 執行董事梁碩玲女士、黎文靖先生、張闖先生及王大樹先生。 债券代码：148951 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 GF SECURITIES CO., LTD. 廣發証券股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1776） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，廣發証券股份有限公司（「本公司」）在深圳 證券交易所網站( http://www.szse.cn )刊發的《廣發証券股份有限公司2025年面向專 業投資者公開發行短期公司債券（第五期）發行結果公告》。茲載列如下，僅供參 閱。 承董事會命 廣發証券股份有限公司 林傳輝 董事長 中國，廣州 2025年6月12日 於本公告日期，本公司董事會成員包括執行董事林傳輝先生、秦力先生、孫曉燕 女士及肖雪生先生；非執行董事李秀林先生、尚書志先生及郭敬誼先生；獨立非 執行董事梁碩玲女士、黎文靖先生、張闖先生及王大樹先生。 特此公告。 （本页以下无正文） 期公司债券（第五 ...

Core Points - The announcement details the payment of interest and principal for the short-term corporate bond issued by GF Securities Co., Ltd. on June 16, 2025 [1] - The bond, referred to as "24 Guang D13," has a coupon rate of 1.95% and the total payment per unit (face value of 1,000 yuan) is 1,012.715068 yuan, including tax [2] - The bondholders will receive a net amount of 1,010.172054 yuan after tax deductions for individual and securities investment fund holders, while non-resident enterprises will receive the full amount [2] Bond Details - The bond has a credit rating of A-1 and the company's credit rating is AAA with a stable outlook [1] - The interest payment period is from October 21, 2024, to June 15, 2025 [1] - The payment will be processed through China Clearing Shenzhen Branch, which will distribute the funds to the designated securities firms or institutions [2] Taxation Information - Individual bondholders are subject to a personal income tax rate of 20% on the interest earned [3] - Non-resident enterprises holding the bond are exempt from corporate income tax on the interest earned during the specified period [4] - Other bondholders are responsible for their own tax payments on interest income [5] Contact Information - The announcement provides contact details for inquiries, including addresses and phone numbers for representatives in Guangzhou and Shenzhen [5]

证券代码：524303 证券简称：25 广发 D7 广发证券股份有限公司 2025 年面向专业投资者公开发行短期公司债券（第五期） 发行结果公告 广发证券股份有限公司（以下简称"发行人"）面向专业投资者公开发行面 值余额不超过人民币 300 亿元（含）的短期公司债券已获得中国证券监督管理委 员会"证监许可〔2025〕818 号"文同意注册。根据《广发证券股份有限公司 2025 年面向专业投资者公开发行短期公司债券（第五期）发行公告》，广发证券股份 有限公司 2025 年面向专业投资者公开发行短期公司债券（第五期）（以下简称"本 期债券"）计划发行规模不超过 30 亿元（含），发行价格为每张 100 元，采取网 下面向专业机构投资者询价配售的方式发行。 本期债券发行时间为 2025 年 6 月 11 日至 2025 年 6 月 12 日，最终实际发行 规模为 30 亿元，票面利率为 1.64%，认购倍数为 3.96 倍。 发行人的董事、监事、高级管理人员、持股比例超过 5%的股东及其他关联 方未参与本期债券认购。承销商华泰联合证券有限责任公司、平安证券股份有限 公司、国泰海通证券股份有限公司及其关联方未参与认购 ...

债券代码：148951 债券简称：24 广 D13 广发证券股份有限公司 2024 年面向专业投资者公开发行短期公司债券 （第六期）（品种二）2025 年兑付兑息及摘牌公告 本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 特别提示： 广发证券股份有限公司 2024 年面向专业投资者公开发行短期公司债券（第 六期）（品种二）（债券简称："24 广 D13"，债券代码：148951，以下简称"本 期债券"）将于 2025 年 6 月 16 日支付 2024 年 10 月 21 日至 2025 年 6 月 15 日 期间的利息及本期债券的本金。为确保本次兑付兑息工作的顺利进行，现将有关 事宜公告如下： 一、本期债券基本情况 1、债券名称：广发证券股份有限公司 2024 年面向专业投资者公开发行短期 公司债券（第六期）（品种二） 2、债券简称及代码：本期债券简称为"24 广 D13"，债券代码为"148951"。 3、债券发行批准机关及文号：中国证券监督管理委员会证监许可〔2023〕 2404 号文。 4、发行期限、规模和利率：本期债券发行期限为 238 天，发行规模为 ...

Group 1 - The core viewpoint of the report is that Guangfa Securities is optimistic about the differentiated biopharmaceutical platform of CStone Pharmaceuticals-B (09966) and the development potential of its ADC drugs, which have shown preliminary clinical efficacy [1] - The company was established in 2015 and focuses on the development, production, and commercialization of innovative anti-tumor biologics, with a highly differentiated internal pipeline covering anti-tumor drugs at various research stages [1] - The first product, KN035 (Envafolimab injection), was launched in November 2021, marking the company's entry into the commercialization phase [1] Group 2 - CStone Pharmaceuticals has developed several globally leading biopharmaceutical technology platforms, including glycoengineered conjugation platform, linker payload platform, bispecific antibody platform, and subcutaneous high-concentration formulation platform, which have differentiated therapeutic advantages [1] - The glycoengineered conjugation platform reduces the production cost of ADC drugs while effectively minimizing toxin release in the circulatory system, enhancing drug safety [1] - Products developed based on this platform, JSKN003 and JSKN016, have entered clinical stages, and the company has upgraded the dual payload technology platform with corresponding products expected to enter clinical trials [1] Group 3 - The HER2 bispecific antibody KN026 is undergoing registration clinical studies for second-line gastric cancer, first-line breast cancer, and neoadjuvant therapy, with a promising path to market [2] - The HER2 bispecific ADC JSKN003 is in phase III clinical trials for breast cancer and platinum-resistant ovarian cancer, demonstrating competitive efficacy in early clinical studies [2] - The HER3/TROP2 bispecific ADC JSKN016 has initiated clinical trials for lung cancer and breast cancer, indicating a broad potential market, while new generation ADCs like JSKN021 (dual payload) and JSKN022 are expected to advance to clinical stages quickly [2]

Group 1 - The core viewpoint of the report is that Beike-W (02423) is expected to achieve adjusted net profit of 7.7 billion yuan and 10.3 billion yuan in 2025 and 2026, representing year-on-year growth of 6% and 34% respectively, with a target price of 59.32 HKD/share and 22.86 USD/share based on a 26x PE ratio for 2025 [1] - Beike's stock-based compensation (SBC) for 2024 is projected to be 2.7 billion yuan, accounting for 38% of the adjusted net profit of 7.2 billion yuan, with a gradual decrease in SBC expected in the following years [1][3] - The core management team received a significant incentive in 2022, resulting in 3.6 billion yuan of deferred expenses to be amortized over five years, which has led to higher reported compensation figures [2] Group 2 - Beike's SBC is expected to decrease to 1.94 billion yuan, 1.78 billion yuan, and 1.47 billion yuan in 2025, 2026, and 2027 respectively, indicating a trend of declining stock-based compensation [3] - When comparing Beike to other internet platforms like JD.com, Meituan, and Tencent, Beike has a lower proportion of employee incentive value relative to adjusted net profit, demonstrating better control over stock-based compensation [4] - Beike has provided a total shareholder return rate of 5.5%, which is significantly higher than its peers, indicating a strong commitment to returning value to shareholders during its growth phase [4]

Group 1 - The core viewpoint of the article is that coal prices are expected to be close to their annual low due to a combination of demand and supply factors, particularly as the summer consumption peak approaches [1] - The report highlights a potential decline in supply, especially from regions like Xinjiang and Indonesia, which may further support the expectation of lower coal prices [1]

Group 1 - The core viewpoint is that the recent equity adjustments in "Huijin" brokerages are expected to drive a new wave of mergers and acquisitions in the securities industry, focusing on administrative and market-based mergers under the same controlling entity [1][3]. - As of June 11, broker stocks showed strong performance, with notable increases in shares such as Xinda Securities (+7.83%) and Industrial Securities (+5.07%) [2][1]. - The China Securities Regulatory Commission has approved Central Huijin Investment Co., Ltd. as the actual controller of several brokerages, including Changcheng Guorui Securities and Dongxing Securities, which has reignited market expectations for mergers [2][1]. Group 2 - Analysts believe that regulatory encouragement for industry consolidation, along with policies aimed at high-quality development, positions mergers and acquisitions as effective means for brokers to achieve external growth and enhance overall industry competitiveness [3]. - The focus is on two main areas: brokerages under the same controlling entity and those with high potential for market-based mergers, indicating a promising outlook for the brokerage and financial technology sectors [3]. - Positive policy signals since the beginning of the year, including interest rate cuts, are expected to support liquidity and boost market confidence, with a forecast for sustained high trading activity through 2025 [3].

港股中资券商股盘中强势，光大证券(06178.HK)涨超9%，弘业期货(03678.HK)涨超8%，广发证券 (01776.HK)涨超6%，中金公司(03908.HK)、招商证券(06099.HK)、华泰证券(06886.HK)均涨超5%。 ...